| 产品名称： | 6.12 |
|---|---|
| 商品货号： | TS140001 |
| Organism： | Mus musculus, mouse |
| Tissue： | spleen |
| Cell Type： | hybridoma: lymphoblast B lymphocyte; somatic cell hybrid |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension, with some loosely adherent cells |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody specifically binds to an extrcellular domain of human vascular endothelial growth factor (VEGF) receptor 1 fms-like tyrosine kinase (Flt-1) U.S. Pat. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Comments： | The antibody specifically binds to an extrcellular domain of human vascular endothelial growth factor (VEGF) receptor 1 fms-like tyrosine kinase (Flt-1) U.S. Pat. 6,365,157; U.S. PAT. 6,448,077.
The 6.12 cell line was deposited at the ATCC as PTA-3344. Progeny from PTA-3344 are available as CRL-13006. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 x 104 viable cells/mL. Adherent cells may be removed by shaking the flask. Maintain cell density between 3 x 104 and 4 x 105 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG1 kappa |
| Name of Depositor： | ImClone Systems Inc. |
| References： | Rockwell P, Goldstein NI. Monoclonal antibodies specific to VEGF receptors and uses thereof. US Patent 6,365,157 dated Apr 2 2002 Rockwell P, Goldstein NI. Chimeric and humanized monoclonal antibodies specific to VEGF receptors. US Patent 6,448,077 dated Sep 10 2002 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | 6.12 |
|---|---|
| 商品货号： | TS140001 |
| Organism： | Mus musculus, mouse |
| Tissue： | spleen |
| Cell Type： | hybridoma: lymphoblast B lymphocyte; somatic cell hybrid |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension, with some loosely adherent cells |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody specifically binds to an extrcellular domain of human vascular endothelial growth factor (VEGF) receptor 1 fms-like tyrosine kinase (Flt-1) U.S. Pat. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Comments： | The antibody specifically binds to an extrcellular domain of human vascular endothelial growth factor (VEGF) receptor 1 fms-like tyrosine kinase (Flt-1) U.S. Pat. 6,365,157; U.S. PAT. 6,448,077.
The 6.12 cell line was deposited at the ATCC as PTA-3344. Progeny from PTA-3344 are available as CRL-13006. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 x 104 viable cells/mL. Adherent cells may be removed by shaking the flask. Maintain cell density between 3 x 104 and 4 x 105 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG1 kappa |
| Name of Depositor： | ImClone Systems Inc. |
| References： | Rockwell P, Goldstein NI. Monoclonal antibodies specific to VEGF receptors and uses thereof. US Patent 6,365,157 dated Apr 2 2002 Rockwell P, Goldstein NI. Chimeric and humanized monoclonal antibodies specific to VEGF receptors. US Patent 6,448,077 dated Sep 10 2002 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
